comparemela.com

Reedv Tuckson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

District Dads Celebrate Fathers during Annual Event

District Dads Celebrate Fathers during Annual Event
washingtoninformer.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtoninformer.com Daily Mail and Mail on Sunday newspapers.

HENRY SCHEIN INC : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 23, 2023, at. | May 25, 2023

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has filed a new investor presentation with the U.S. Securities and Exchange Commission in connection with its 2021 Annual Meeting of Stockholders (“Annual Meeting”). The presentation is available at https://investors.adverum.com/shareholder-services/annual-meeting.

Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch

SONIC’S NOMINEES ARE NOT ADDITIVE TO THE ADVERUM BOARD As you know, The Sonic Fund II, L.P. has proposed nominees that, if elected, together with its two designees appointed in 2019, would constitute more than half of the Board. Sonic’s nomination of three candidates for election to the Board is not in the best interest of our stockholders – their election would diminish the diversity and the needed skills and experience represented on our Board, and there is no reason to believe they would enhance our efforts to advance ADVM-022 toward commercialization and deliver global access to our vision-saving gene therapy.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.